Meformin and predictive biomarkers in the broad spectrum of internal diseases

Czech version

Authors: Andrej Dukát ¹; Juraj Payer ¹; Peter Jackuliak ¹; Hana Štefaničková ²; Ján Kyselovič ³; Andrea Gažová ³; Martin Jankovský ¹; Samuel Nachtmann ¹; Patrik Valent ¹; Juraj Smaha ¹
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava ¹; Institute of Science and Technology Austria (ISTA), Klosterneuburg, Rakúsko ²; Ústav farmakológie a klinickej farmakológie LF UK v Bratislave ³
Published in: Diab Obez 2025; 25(2): 95-101
Category: Reviews

Overview

Metformin is the most common prescribed glucose-lowering drug in the clinical practice, used also for the prevention of type 2 diabetes mellitus in people at high risk Majority of his effect is attributable to lower body weight in a sustained manner. During its usage in the clinical practice of the half century molecular mechanisms are still not completely known. Similarly except of glycemic measures, no biomarker for its presence or dose has been found. However potential value of GDF15 as a biomarker for metformin have been proposed.

Keywords:

biomarkers –GDF15

Sources

Knowler WC, Barrett-Connor E, Fowler SE et al. [Diabetes Prevention Program Research Group]. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393–403. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa012512>.

Gandini S, Puntoni M, Heckman-Stoddard BM et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 2014; 7(9): 867–885. Dostupné z DOI: <http://dx.doi.org/10.1158/1940–6207.CAPR-13–0424>.

Steinberg GR. AMPK and the endocrine control of energy metabolism. Moll Cell Endocrinol 2013; 366(2): 125–126. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mce.2013.01.003>.

Gerstein HC, Bosch J, Dagenais GR et al. [ORIGIN Trial Investigators]. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367(4): 319–328. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1203858>.

Breit SN, Johnen H, Cook AD et al. The TGF-β superfamily cytokine, MIC-1/GDF15: a pleiotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 2011; 29(5): 187–195. Dostupné z DOI: <http://dx.doi.org/10.3109/08977194.2011.607137>.

Hsu JY,Crawley S, Chen M et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 2017; 550(7675): 255–259. Dostupné z DOI: <http://dx.doi.org/10.1038/nature24042>.

Konopka AR, Esponda RR, Robinsom MM et al. Hyperglucagonaemia Mitigates the Effect of Metformin on Glucose Prediction in Prediabetes. Cell Rep 2016; 15(7): 1394–1400. Dostupné z DOI: <http://dx.doi.org/10.1016/j.celrep.2016.04.024>.

Preiss D, Lloyd SM, Ford J et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2014; 2(2): 116–124. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(13)70152–9>.

Massollo M, Marini C, Brignone M et al. Metformin temporal and localized effects on gut glucose metabolism of metformin assessed using 18F-FDG PET in mice J Nucl Med 2013; 54(2): 259–266. Dostupné z DOI: <http://dx.doi.org/10.2967/jnumed.112.106666>.

Buse JB, DeFronzo RA, Rosenstock J et al. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care 2016; 39(2): 198–205. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–0488>.

Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12(8): 553–564. Dostupné z DOI: <http://dx.doi.org/10.2337/diacare.12.8.553>.

Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int 2004; 21(3): 115–117.

Zhou K, Donnelly L, Yang J et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014; 2(6): 481–487. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(14)70050–6>.

HC, Pare G, Hess S et al. Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. Diabetes Care 2017; 40(2): 280–283. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–1682>.

Wang D, Day EA, Towsend LK et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol 2021; 17(10): 592–609. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574–021–00529–7>.

Colt AP, Chen M, Taskar P et al. GDF15 medites the effects of metformin on body weight and energy balance. Nature 2020; 578(7795): 444–448. Dostupné z DOI: <http://dx.doi.org/10.1038/s41586–019–1911-y>.

Klein AB, Kleinert M, Richter EA et al. GDF15 in appetite and exercise: essential player or coincidental bystander? Endocrinology 2022; 163(1): bgab242. Dostupné z DOI: <http://dx.doi.org/10.1210/endocr/bqab242>.

[Diabetes Prevention Program Research Group]. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35(4): 731–737. Dostupné z DOI: <http://dx.doi.org/10.2337/dc11–1299>.

Ning HH, Le J, Young CH A et al. The effects of metformin on simple obesity: a metaanalysis. Endocrine 2018; 62(3): 528–534. Dostupné z DOI: <http://dx.doi.org/10.1007/s12020–018–1717-y>.

Coll AP, Chen M, Taskar P et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 2020; 578(7795): 444–448. Dostupné z DOI: <http://dx.doi.org/10.1038/s41586–019–1911-y>.

Klein AB, Nicolaisen TS, Johann K et al. The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance. Cell Rep 2022; 40(8): 111258. Dostupné z DOI: <http://dx.doi.org/10.1016/j.celrep.2022.111258>.

Yoval-Sánchez B, Ansari F, Lange D et al. Effects of meformin on intact mitochondria from liver and brain: concept revisited. Eur J Pharmacol 2022; 931 : 175177. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejphar.2022.175177>.

McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia 2016; 59(3): 426–435. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–015–3844–9>.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017; 60(9): 1577–1585. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–017–4342-z>.

Preiss D, Dawed A, Welsh P et al. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes Obes Metab 2017; 19(3): 356–363. Dostupné z DOI: <http://doi 10.1111/dom.12826>.

Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nature Rev Endocrinol 2023; 19(8): 460–476. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574–023–00833–4>.

Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–1589. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0806470>.

Rohm TV, Meier DT, Olefsky et al. Inflammation in obesity, diabetes, and related disorders. Immunity 2022; 55(1): 31–55. Dostupné z DOI: <http://dx.doi.org/10.1016/j.immuni.2021.12.013>.

Dukát A, Jackuliak P, Kyselovič J et al. Kardiovaskulárny-renálny-metabolický syndróm: novodefinovaná klinická jednotka. Lek Obz 2025; 74(1): 21–27.

Petrelli F, Grappasonni I, Nguyen CTT et al. Metformin and Covid-19: a systematic review with meta-analysis. Acta Biomed 2023; 94(S3): e2023138. Dostupné z DOI: <http://dx.doi.org/10.23750/abm.v94iS3.14405>.

Flory J, Lipska K. Metformin in 2019. JAMA 2019; 321(19): 1926–1927. Dostupné z DOI: <http://dx.,doi.org/10.1001/jama.2019.3805.

Kristófi R, Eriksson JW. Metformin as an anti-inflammatory agent: a short review. J Endokrinol 2021; 251(2): R11-R22. Dostupné z DOI: <http://dx.doi.org/10.1530/JOE-21–0194>.

deMaraňón AM, Diaz-Pozo P, Canet F et al. Metformin modulates mitochondrial function and mitophagy in periphral blood mononuclrear cells from type-2 diabetic patients. Redox Biol 2022; 53 : 102342. Dostupné z DOI: <http://dx.doi.oirg/10.1016/j.redox.2022.102342>.

Bhansali S, Bhansali A, Hhawan V. Metformin promotes mitophagy in mononuclear cells: a potential in vitro model for unraveling metformin´s mechanism of action. Ann N Y Acad Sci 2020; 1463(1): 23–36.Dostupné z DOI: <http://dx.doi.org/10.1111/nyas.14141>.

Menegazzo L, Scattolini V, Cappellari R et al. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol 2018; 55(6): 593–601. Dostupné z DOI: <http://dx.doi.org/10.1007/s00592–018–1129–8>.

Dukát A, Kyselovič J, Gažová A et al. Expozóm ako nový rizikový faktor klinickej medicíny v súčasnosti. Lek Obz 2025; 74(5): 204–214.

Franceschi C, Garagnani P, Parini R et al. Inflammaging: a new immune -metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018; 14(10): 576–590. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574–018–0059–4>.

Dukát A, Štefaničková H, Payer J et al. Senescencia a možnosti senolytickej liečby. Lek Obz 2025; 74(7): 274–281.

Dukát A, Štefaničková H, Payer J. Bunková senescencia a starnutie Lek Obz 2025 : 74(8): 318–322.

Frasca D, Diaz A, Romero M et al. Metformin enhances B cell function and antibody responses of elderly individuals with type-2 diabetes mellitus. Front Aging 2021; 2 : 715981. Dostupné z DOI: <http://dx.doi.org/10.3389/fragi.2021.715981>.

Mueller NT, Differding MK, Zhang M et al. Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: a randomized trial. Diabetes Care 2021; 44(7): 1462–1471. Dostupné z DOI: <http://dx.doi.org/10.2337/dc20–2257>.

Zhang Q, Hu N. Effects of metformin on the gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Metab Syndr 2020; 13 : 5003–5014. Dostupné z DOI: <http://dx.doi.org/10.2147/DMSO.S286430.10.2147/DMSO.S286430>.

Forslund K, Hildebrand F, Nielsen T et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528(7581): 262–266. Dostupné z DOI: <http://dx.doi.org/10.1038/nature15766>.

Elbere I, Kalnina I, Silamikelis I et al.: Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. PLoS ONE 2018; 13(9): e0204317. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0204317>.

Wu H, Esteve E, Tremaroli V et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 2017; 23(7): 850–858. Dostupné z DOI: <http://dx.doi.org/10.1038/nm.4345>.

Yang Y,Liu S, Wang Y et al. Changes of saliva microbiota in the onset and after the treatment of diabetes in patients with periodontitis. Aging 2020; 12(13): 13090–13114. Dostupné z DOI: <https://doi.org/10.18632/aging.103399>.

DeFronzo RA, Buse JB, Kim T et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 2016; 59(8): 1645–1654. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–016–3992–6>.

Shin NR, Lee JCH, Lee JY et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis. Gut 2014; 63(5): 727–735. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2012–303839>.

Dukát A, Payer J, Bernadič M et al. Červný mikrobióm a kardiovaskulárny systém. Lek Obz 2024; 73(1): 21–25.

Connolly B, McCreight L, Slieker RC et al. The influence of metformin treatment on the circulating proteome. EBioMedicine (Lancet 2025); 118 : 105859. Dostupné z DOI: <http//doi.org/10.1016/j.ebiom.2025.105859>.

Kulkarni AS, Gubbi S et al. Benefits of metformin in attenuating the hallmarks of aging. Cell Metab 2020; 32 : 15(1)-30. Dostupné z DOI: <http://dx.doi.oirg/10.1016/j.cmet.2020.04.001>.

Elizalde-Velázquez GA, Gómez-Oliván L. Occurence toxic effects and removal of metformin in aquatic environments in the world: recet trends and perspectives. Sci Total Environ 2020; 702 : 134924. Dostupné z DOI: <http://dx.doi.org/10.1016/j.scitotenv.2019.134924>.

Balakrishnan A, Sillanpää M, Jacob MM et al. Metformin as an emerging concern in wastewater: occurence, analysis and treatment methods. Environ Res 2022; 213 : 113613. Dostupné z DOI: <http://dx.doi.org/10.1016/j.envres.2022.113613>.

Lalau JD, Al-Salameh A, Hadjadh S et al. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab 2021; 47(5): 101216. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabet.2020.101216>.

Zhu L, She ZG, Cheng X et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 31(6): 1068–1077. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2020.04.021>.

Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019 : 27(11): 1578–1589. Dostupné z DOI: <http://dx.doi.org/10.1016/j.joca.2019.06.011>.

Lim YZ, Wang Y, Estee M et al. Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies. Osteoarthritis Cartilage 2022; 30(1): 1434–1442. Dostupné z DOI: <http://dx.doi.org/10.1016/j.joca.2022.05.005>.

Markowicz-Piasecka M, Huttunen KM, Mateusiak L et al. Is metformin a perfect drug? Updates in pharmacokinretics and pharmacodynamics. Curr Pharmaceut Des 2017; 23(17): 2532–2550. Dostupné z DOI: <http://dx.doi.org/10.2174/1381612822666161201152941>.

Li J, Zhang B, Liu WX et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann Rheum Dis 2020; 79(5): 635–645. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2019–216713>.

H, Ding X, Terkeltaub R et al. Exploration of metformin as novel therapy for osteoarthritis: preventing cartillage degeneration and reducing pain behavior. Arthritis Res Ther 2020; 22(1): 34. Dostupné z DOI: <http://dx.doi.org/10.1186/s13075–020–2129-y>.

Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets 2015 : 15(3): 196–205. Dostupné z DOI: <http://dx.doi.org/10.2174/1871530315666150316124019>.

McCreight LJ, Mari A, Coppin L et al. Metformin increases fasting glucose clearance and endogenous glucose production in non-diabetic individuals. Diabetologia 2020; 63(2): 444–447. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–019–05042–1>.

Dukát A, Payer J, Šimko F. GDF15: nový prediktívny biomarker pre diabetes mellitus 2. typu v klinickej praxi. Diab Obez 2020; 20(40): 88–92.